The main misconceptions in cardiology concerning obesity

This article reviews common myths and stereotypes about obesity that distort the understanding of its causes and pathogenesis and contribute to the disease stigmatization among the cardiology medical community. Obesity is a chronic, relapsing, multifactorial disease characterized by excessive formation of adipose tissue, progressing in its natural course and, as a rule, having an increased cardiometabolic risk. For effective prevention of complications, it is necessary to start treating obesity at the risk and pre-disease stages (abdominal obesity and overweight). The causes of obesity include genetic, metabolic, social and environmental factors. The review emphasizes that obesity is not exclusively a consequence of a lack of willpower in choosing food products according to the rules of healthy eating or a sedentary lifestyle. Many stereotypes, such as the idea that all patients with excess body weight have an alimentary genesis of the disease and all clinical "findings" are associated with obesity, do not correspond to reality and hinder effective prevention and treatment strategies. No other chronic non-communicable disease is as stigmatized as obesity. Moreover, despite the development of modern pharmacotherapy, behavioral therapy for obesity, and bariatric surgery, there is high clinical inertia in timely initiation of treatment for this disease. Body weight is becoming the same target indicator in general therapeutic practice as blood pressure or glycemia. Modern medicine dictates the need to rely solely on the evidence base to refute myths in order to create a more inclusive and supportive environment that promotes the health and well-being of patients.

1. GBD 2019 Risk Factors Collaborators. Global burden of 87 risk factors in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2020;396(10258):1223-49. DOI: 10.1016/S0140-6736(20)30752-2.

2. Okunogbe A, Nugent R, Spencer G, et al. Economic impacts of overweight and obesity: current and future estimates for 161 countries. BMJ Glob Health. 2022;7(9):e009773. DOI: 10.1136/bmjgh-2022-009773.

3. Drapkina OM, Kontsevaya AV, Kalinina AM, et al. 2022 Prevention of chronic non-communicable diseases in the Russian Federation. National guidelines. Cardiovascular Therapy and Prevention. 2022;21(4):3235 (In Russ.) DOI: 10.15829/1728-8800-2022-3235.

4. Aune D, Sen A, Prasad M, et al. BMI and all-cause mortality: systematic review and non-linear dose-response meta-analysis of 230 cohort studies with 3.74 million deaths among 30.3 million participants. BMJ. 2016;353:i2156. DOI: 10.1136/bmj.i2156.

5. Drapkina OM, Kupreyshvili LV, Fomin VV. Body composition and its role in development of metabolic disorders and cardiovascular diseases. Cardiovascular Therapy and Prevention. 2017;16(5):81-5 (In Russ.) DOI: 10.15829/1728-8800-2017-5-81-85.

6. Golounina OO, Fadeev VV, Belaya ZhE. Modern guidelines for the diagnosis of sarcopenia. Klinicheskaya meditsina. 2023;101(4-5):198-207. (In Russ) DOI: 10. 30629/0023-2149-2023-101-4-5-198-207.

7. Drapkina OM, Kontsevaya AV, Kalinina AM, et al. Comorbidity of patients with noncommunicable diseases in general practice. Eurasian guidelines. Cardiovascular Therapy and Prevention. 2024;23(3):3996 (In Russ) DOI: 10.15829/1728-8800-2024-3996.

8. Koskinas KC, Van Craenenbroeck EM, Antoniades C, et al. Obesity and cardiovascular disease: an ESC clinical consensus statement. Eur J Prev Cardiol. 2024:zwae279. DOI: 10.1093/eurjpc/zwae279.

9. Burridge K, Christensen SM, Golden A, et al. Obesity history, physical exam, laboratory, body composition, and energy expenditure: an Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2022. Obes Pillars. 2022;1:100007. DOI: 10.1016/j.obpill.2021.100007.

10. Drapkina OM, Maksimova OA, Sheptulina AF, Dzhioeva ON. Bioimpedance analysis of body composition: what should general practitioner know? Russian Journal of Preventive Medicine. 2022;25(10):91-6 (In Russ.) DOI: 10.17116/profmed20222510191.

11. Shuster A, Patlas M, Pinthus JH, Mourtzakis M. The clinical importance of visceral adiposity: a critical review of methods for visceral adipose tissue analysis. Br J Radiol 2012;85(1009):1-10. DOI: 10.1259/bjr/38447238.

12. Mayoral LP, Andrade GM, Mayoral EP, et al. Obesity subtypes, related biomarkers & heterogeneity. Indian J Med Res. 2020;151(1):11-21. DOI: 10.4103/ijmr.IJMR_1768_17.

13. Caballero B. Humans against Obesity: Who Will Win? Adv Nutr. 2019;10(suppl_1):S4-S9. DOI: 10.1093/advances/nmy055.

14. Tirthani E, Said MS, Rehman A. Genetics and Obesity. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan–.

15. Mahmoud AM. An Overview of Epigenetics in Obesity: The Role of Lifestyle and Therapeutic Interventions. Int J Mol Sci. 2022;23(3):1341. DOI: 10.3390/ijms23031341.

16. Calcaterra V, Cena H, Rossi V, et al. Ultra-Processed Food, Reward System and Childhood Obesity. Children (Basel). 2023;10(5):804. DOI: 10.3390/children10050804.

17. Olateju IV, Opaleye-Enakhimion T, Udeogu JE, et al. A systematic review on the effectiveness of diet and exercise in the management of obesity. Diabetes Metab Syndr. 2023;17(4):102759. DOI: 10.1016/j.dsx.2023.102759.

18. Fitch AK, Bays HE. Obesity definition, diagnosis, bias, standard operating procedures (SOPs), and telehealth: an Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2022. Obes Pillars. 2022;1:100004. DOI: 10.1016/j.obpill.2021.100004.

19. Bays H. Adiposopathy, "sick fat," Ockham’s razor, and resolution of the obesity paradox. Curr Atheroscler Rep. 2014;16(5):409. DOI: 10.1007/s11883-014-0409-1.

20. Freshwater M, Christensen S, Oshman L, Bays HE. Behavior, motivational interviewing, eating disorders, and obesity management technologies: An Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2022. Obes Pillars. 2022;2:100014. DOI: 10.1016/j.obpill.2022.100014.

21. Thaler RH, Sunstein CR, Balz JP. Choice architecture. In: Shafir E (editor), The behavioral foundations of public policy. 2012. DOI: 10.2139/ssrn.1583509.

22. Faith MS, Berkowitz RI, Stallings VA, et al. Eating in the absence of hunger: a genetic marker for childhood obesity in prepubertal boys? Obesity (Silver Spring). 2006;14(1):131-8. DOI: 10.1038/oby.2006.16.

23. Eliashevich SO, Nuňez Araujo DD, Drapkina OM. Eating behavior: disorders and how to assess them. Cardiovascular Therapy and Prevention. 2023;22(8):3663 (In Russ) DOI: 10.15829/1728-8800-2023-3663.

24. Ursell LK, Metcalf JL, Parfrey LW, Knight R. Defining the human microbiome. Nutr Rev. 2012;70 (Suppl 1):S38-S44. DOI: 10.1111/j.1753-4887.2012.00493.x.

25. Karczewski J, Zielinska A, Staszewski R, et al. Obesity and the Brain. Int J Mol Sci. 2022;23(11):6145. DOI: 10.3390/ijms23116145.

26. Shetye B, Hamilton FR, Bays HE. Bariatric surgery, gastrointestinal hormones, and the microbiome: an obesity medicine association (OMA) clinical practice statement (CPS) 2022. Obes Pillars. 2022;2:100015. DOI: 10.1016/j.obpill.2022.100015.

27. Li D, Li Y, Yang S, et al. Diet-gut microbiota-epigenetics in metabolic diseases: From mechanisms to therapeutics. Biomed Pharmacother. 2022;153:113290. DOI: 10.1016/j.biopha.2022.113290.

28. Vallianou N, Dalamaga M, Stratigou T, et al. Do Antibiotics Cause Obesity Through Long-term Alterations in the Gut Microbiome? A Review of Current Evidence. Curr Obes Rep. 2021;10(3):244-62. DOI: 10.1007/s13679-021-00438-w.

29. Allegretti JR, Kassam Z, Mullish BH, et al. Effects of fecal microbiota transplantation with oral capsules in obese patients. Clin Gastroenterol Hepatol. 2020;18(4):855-63.e2. DOI: 10.1016/j.cgh.2019.07.006.

30. Sehgal K, Khanna S. Gut microbiota: a target for intervention in obesity. Expert Rev Gastroenterol Hepatol. 2021;15(10):1169-79. DOI: 10.1080/17474124.2021.1963232.

31. Sahle Z, Engidaye G, Shenkute Gebreyes D. Fecal microbiota transplantation and next-generation therapies: A review on targeting dysbiosis in metabolic disorders and beyond. SAGE Open Med. 2024;12:20503121241257486. DOI: 10.1177/20503121241257486.

32. Koliada A, Syzenko, G, Moseiko V, et al. Association between body mass index and Firmicutes/Bacteroidetes ratio in an adult Ukrainian population. BMC Microbiol. 2017;17(1):120. DOI: 10.1186/s12866-017-1027-1.

33. Yan H, Qin Q, Chen J, et al. Gut Microbiome Alterations in Patients With Visceral Obesity Based on Quantitative Computed Tomography. Front Cell Infect Microbiol. 2022;11:823262. DOI: 10.3389/fcimb.2021.823262.

34. Wu GD, Chen J, Hoffmann C, et al. Linking long-term dietary patterns with gut microbial enterotypes. Science. 2011;334(6052):105-8. DOI: 10.1126/science.1208344.

35. De Filippo C, Cavalieri D, Di Paola M, et al. Impact of diet in shaping gut microbiota revealed by a comparative study in children from Europe and rural Africa. Proc Natl Acad Sci USA. 2010;107(33):14691-6. DOI: 10.1073/pnas.1005963107.

36. Kaiser T, Nalluri H, Zhu Z, Staley C. Donor Microbiota Composition and Housing Affect Recapitulation of Obese Phenotypes in a Human Microbiota-Associated Murine Model. Front Cell Infect Microbiol. 2021;11:614218. DOI: 10.3389/fcimb.2021.614218.

37. Phelan SM, Burgess DJ, Yeazel MW, et al. Impact of weight bias and stigma on quality of care and outcomes for patients with obesity. Obes Rev. 2015;16(4):319-26. DOI: 10.1111/obr.12266.

38. Galicia-Garcia U, Benito-Vicente A, Jebari S, et al. Pathophysiology of type 2 diabetes mellitus. Int J Mol Sci. 2020;21(17):6275. DOI: 10.3390/ijms21176275.

39. Singh S, Shankar R, Singh GP. Prevalence and associated risk factors of hypertension: a cross-sectional study in urban Varanasi. Int J Hypertens. 2017;2017:5491838. DOI: 10.1155/2017/5491838.

40. Chazova IE, Chikhladze NM, Blinova NV, et al. Eurasian clinical guidelines for the diagnosis and treatment of secondary (symptomatic) forms of arterial hypertension (2022). Eurasian heart journal. 2023;(1):6-65 (In Russ.) DOI: 10.38109/2225-1685-2023-1-6-65.